Ironwood Pharmaceuticals, Inc. (IRDW), and Almirall, S.A. Wednesday said the European Commission has granted permission to market drug Constella for the treatment of irritable bowel syndrome with constipation, or IBS-C, in adults. This decision follows the positive recommendation for the drug received from the The European Medicines Agency in late September this year.
IBS, known to affect nearly 15 million adults in the European Union, is characterized by abdominal pain, discomfort, swelling or constipation. Until now, there are very few affective treatments for the disease in the European Union, said the companies in a statement.
Further, first launches of the drug in Europe are expected to occur in the first half of 2013.
For comments and feedback: editorial@rttnews.com